Latest Commercialization News

Page 26 of 537
Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.
Ada Torres
Ada Torres
30 Apr 2026
Bindi Metals has confirmed bonanza-grade gold mineralisation at its Ravni Gold Project in Serbia, defining a 3 km high-grade corridor and preparing for maiden drilling with a preferred contractor in place.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Astron Limited has updated its Donald Rare Earth and Mineral Sands Project with a refreshed Bankable Feasibility Study showing a pre-tax NPV8 of AUD 759 million, strengthened Indigenous agreements, and a targeted Final Investment Decision in Q2 2026.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Forte Energy has rapidly expanded its oil and gas exploration portfolio in Alaska’s National Petroleum Reserve, acquiring over 156,000 acres including the billion-barrel Harrier Prospect and adjacent leases to Umiat Oil Field, while securing significant cost savings through lease fee suspensions.
Maxwell Dee
Maxwell Dee
30 Apr 2026
ABx Group has made significant strides in its rare earths and clean fluorine chemical projects, receiving high-purity product validation and advancing pilot plant construction, while progressing bauxite mining approvals across multiple states.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Blue Star Helium has completed Stage 1 of its Galactica development, tying six wells into the Pinon Canyon facility and starting spot-priced helium sales. The company raised A$10 million to fund further project expansion and working capital.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.
Ada Torres
Ada Torres
30 Apr 2026
Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.
Ada Torres
Ada Torres
30 Apr 2026
Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.
Ada Torres
Ada Torres
30 Apr 2026
archTIS delivered a 231% year-on-year increase in annual recurring revenue to A$15.1 million, marked by the full deployment of its US Department of Defense custom software and a significant contract with a US-European military alliance.
Sophie Babbage
Sophie Babbage
30 Apr 2026
ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.
Ada Torres
Ada Torres
30 Apr 2026
Firebird Metals has locked in a purpose-built industrial facility in Osborne Park, Perth, to house its pioneering Australian Demonstration Plant, the only fully integrated manganese concentrate-to-cathode active material facility outside China.
Maxwell Dee
Maxwell Dee
30 Apr 2026